Navigation Links
Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
Date:5/5/2009

g improved treatments for diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

About the NIH and NIAID

The NIH -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov. NIAID conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.


'/>"/>
SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
2. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
3. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
4. Psylin Neurosciences Commences Development of Compound for Depression
5. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
6. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
7. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
8. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... , August 31, 2015 , ... Frau   für chirurgische   Behandlung     ... 7-90   werden für eine   verheerende   Geburtsverletzung ... behandeln und die Anzahl ausgebildeter Chirurgen in Kenia bis ... gab heute bekannt, dass  Action on Fistula  seit ihrem ...
(Date:8/28/2015)... ... August 28, 2015 , ... Pittcon is pleased to announce ... session on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical & Scientific Instruments ... and scientific instruments show which will be held at International Conference Hall in ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City Animal Health ... animal health companies to hear from animal health companies with the newest technology. ... licensing agreements or distribution contracts. This meeting is one of the only ...
(Date:8/27/2015)... , Aug. 27, 2015 The National ... patient,s eyes—and life—were saved by doctors at Vanderbilt University ... with NNFF, NovaBay Pharmaceuticals and Dr. John Crew ... at Seton Medical Center in Daly ... used a breakthrough approach, pioneered by Dr. Crew, that ...
Breaking Biology Technology:Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3
... of Anesiva,s Needle-Free Technology, SOUTH SAN ... Anesiva, Inc. (Nasdaq: ANSV ) and ... entered into an,agreement granting Particle Therapeutics a ... into its needle-free,intradermal delivery system for glucagon, ...
... 30 Medarex, Inc.,(Nasdaq: MEDX ) announced today ... Partners Healthcare Conference at 11:30 AM Eastern Time on,Wednesday, ... the Four,Seasons Hotel in Boston, Massachusetts. Medarex,s presentation will ... the Webcast page in,the Investor Relations section of the ...
... Aug. 30 Micromet, Inc.,(Nasdaq: MITI ), ... proprietary antibody-based products for cancer, inflammation and,autoimmune diseases, ... Executive Officer of Micromet, will present at the ... on Wednesday,September 5, 2007 at 9:50am Eastern time ...
Cached Biology Technology:Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 2Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 3Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug 4Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007 2Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference 2
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... of the most frustrating problems faced by doctors who treat ... More than 38,000 people in the United States die of ... desperately needed. For almost three decades, scientists and physicians ... mutated in virtually all pancreatic cancers, making it an important ...
... known that large volcanic explosions can affect the weather ... the air. Some suspect that extended "volcanic winters" ... In the summer following Indonesia,s 1815 Tambora ... England, and the 1991 blowout of the Philippines, Mount ...
... Calif.Calcium regulates many critical processes within the body, including ... But too much calcium can be a bad thing. ... diseases, such as severe muscle weakness, a fatal reaction ... intense X-rays from the Stanford Synchrotron Radiation Lightsource (SSRL) ...
Cached Biology News:UNC team discovers promising target for new pancreatic cancer treatments 2Volcanic eruptions affect rainfall over Asian monsoon region 2Volcanic eruptions affect rainfall over Asian monsoon region 3X-rays offer first detailed look at hotspots for calcium-related disease 2
... NanoMate 100 robotic system and disposable ESI ... of the capabilities of electrospray mass spectrometers ... with MS allows users to either speed ... and peptide mapping applications, or long acquisition ...
... RTS AviTag E. coli Biotinylation Kit, Linear Template ... E. coli expression kits. (Cat. No. 3 186 ... to rapidly generate linear expression constructs by PCR ... on a combination of T7 RNA polymerase and ...
... enables sensitive and specific detection of microRNAs ... in situ detection probes have high binding ... sensitive detection of miRNAs. Specific in situ ... mounts, thin sections, single cells and in ...
... the major proteolytic system in the ... catalyzes the selective degradation of short-lived ... of proteins with abnormal conformation (Hershko ... critical protease in this pathway is ...
Biology Products: